Apeliotus Vision Science
Apeliotus is commercializing a novel diagnostic for early detection of a blinding eye disease called age-related macular degeneration (AMD).
AMD is the leading cause of adult blindness in developed countries. It affects over 30 million people worldwide, including one in six over age 65 and one in three over age 75. Despite the tremendous value of early detection, there is currently no good means for diagnosis before significant vision loss has already occurred. Our AdaptDx diagnostic can detect and track AMD from its earliest stages allowing early intervention.